Development of a Breath Analyzer for Asthma Screening

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2006 by Ekips Technologies.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
American Lung Association
Information provided by:
Ekips Technologies
ClinicalTrials.gov Identifier:
NCT00386737
First received: October 11, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted
  Purpose

Annually, asthma is responsible for 1 million emergency room visits, 400,000 hospitalizations, and 5000 deaths according to the NHLBI. In addition, 10 million missed school-days per year and 100 million days of restricted activity are attributed to this disease. While there is no known cause or cure for asthma, recent studies have shown that hospitalizations and emergency room visits can be reduced by as much as 78% and 73%, respectively, when the disease is properly managed. According to the EPA, the occurance of children with asthma more than doubled the rate of two decades ago; in 2001 the percentage of asthmatic children was 8.7% (6.3 million children).

Properly managing asthma is nontrivial and can often require an asthma specialist. The difficulty in diagnosing and managing asthma lies primarily in the lack of available clinical technologies capable of assessing airway inflammation, an early and persistent component of asthma. Accordingly, the National Institutes of Health (NIH) guidelines for the diagnosis and management of asthma strongly recommend long term anti-inflammatory therapies, such as oral or inhaled corticosteroids, to reverse airway inflammation in an effort to prevent irreversible airway damage, termed “airway remodeling”. The medical community has expressed the need for more objective and noninvasive measures of airway inflammation for diagnosing asthma and monitoring the effectiveness and compliance of anti-inflammatory therapies.

The clinical research plan is designed to evaluate airway inflammation associated with asthma. In this human subjects study, a non-invasive exhaled breath analysis sensor, called the Breathmeter, will be used to measure eNO concentrations in children and adults (ages 4-65) with a broad range of respiratory disorders as well as those with no known respiratory disorders. Breath donations will be simple and straightforward presenting little to no discomfort to volunteers.


Condition Phase
Asthma
Phase 0

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: Development of a Breath Analyzer for Asthma Screening

Resource links provided by NLM:


Further study details as provided by Ekips Technologies:

Estimated Enrollment: 2000
Study Start Date: September 2004
Estimated Study Completion Date: February 2007
Detailed Description:

The study plan is divided into two sections: in-clinic studies and large-scale outreach screening.

(A). Clinical Studies The clinical study is intended to obtain data characterizing eNO concentrations within individual groups of subjects listed in the inclusion criteria. The type of this study is “non-invasive”, and the study design is “diagnosis/ treatment monitoring, and efficacy”. The study will seek to recruit subjects who fall into one of the categories listed in the inclusion criteria below. The number of subjects (n) to be recruited for each category is given and is estimated based on the past number of subjects mainly at the Ekips Technologies, The Oklahoma Allergy & Asthma Clinic, and the Norman Lung Center sites.

Inclusion Criteria (Total Number of Subjects, n = 700)

Both genders are eligible for this study:

  1. Healthy subjects (n=120)
  2. Asthma (Total n=450) [diagnosed according to NHLBI/ NAEPP Guidelines (1998)]

    1. Non-treated or B2-agonist treated asthmatics (n=150),
    2. Glucocorticoid treated asthmatics, (n=150),
    3. Leukotriene Antagonist treated asthmatics, (n=75),
    4. Glucocorticoid and Leukotriene Antagonists treated asthmatics, (n= 75).
  3. Acute respiratory illnesses (n=65

    a) Sinusitis (Acute and Chronic), b) Influenza, c) Common cold, d)Pneumonia, e)Related symptoms, but no diagnosis.

  4. Allergies (n=65) a) Atopic dermatitis, b) Allergic rhinitis, c) Seasonal allergies.

Healthy Subjects Recruiting

Healthy subjects will be recruited from visitors and patients at the study sites. Visitors may include relatives or friends accompanying patients. Healthy employees at the study sites may be asked to participate in the study. Patients, visitors, and employees will be told that do not have to participate if they do not want to.

Exclusion Criteria

Subjects younger than 4 and older than 65 will be excluded from the study. Pregnant women will also be excluded from the study.

Duration of Participation

For each visit, the participant in the study will be asked to donate up to 3 breath samples for the first visit. The total time required for breath donations and measurements will be about 5 minutes. An additional five minutes of a subject’s time are needed to complete a short interview if the information needed is not already available.

Asthmatic or suspected asthmatic patients, both treated and non-treated will be asked to donate breath during additional visits if convenient. Follow-up measurements may be performed during regularly scheduled office visits.

  Eligibility

Ages Eligible for Study:   4 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects (n=120)
  • Asthma (Total n=450) [diagnosed according to NHLBI/ NAEPP Guidelines (1998)]

    • Non-treated or B2-agonist treated asthmatics (n=150),
    • Glucocorticoid treated asthmatics, (n=150),
    • Leukotriene Antagonist treated asthmatics, (n=75),
    • Glucocorticoid and Leukotriene Antagonists treated asthmatics, (n= 75).
  • Acute respiratory illnesses (n=65

    • Sinusitis (Acute and Chronic),
    • Influenza,
    • Common cold,
    • Pneumonia,
    • Related symptoms, but no diagnosis.
  • Allergies (n=65)

    • Atopic dermatitis,
    • Allergic rhinitis,
    • Seasonal allergies.

Exclusion Criteria:

  • Younger than 4
  • Older than 65
  • Pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00386737

Contacts
Contact: Tanya Reich, BS (405) 307-8803 ext 114 treich@ekipstech.com
Contact: G. Carl Gibson, BBA (405) 307-8803 ext 110 cgibson@ekipstech.com

Locations
United States, Oklahoma
Ekips Technologies, Inc. Recruiting
Norman, Oklahoma, United States, 73069
Contact: Tanya Reich, BS    405-307-8803 ext 114    treich@ekipstech.com   
Contact: G. Carl Gibson, BBA    (405) 307-8803 ext 110    cgibson@ekipstech.com   
Sponsors and Collaborators
Ekips Technologies
American Lung Association
Investigators
Principal Investigator: Khosrow Namjou, Ph.D. Ekips Technologies, Inc.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00386737     History of Changes
Other Study ID Numbers: NIH-2-R44-HL070344-02
Study First Received: October 11, 2006
Last Updated: October 11, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by Ekips Technologies:
Asthma
Breath Testing
Laser Spectroscopy
eNO
Nitric Oxide
Lower Airway Inflammation
Carbon Dioxide
CO2

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on July 28, 2014